Cantor Fitzgerald analyst Brandon Folkes downgraded Amryt Pharma to Neutral from Overweight with a price target of $14.75, down from $25, following the announced acquisition by Chiesi Farmaceutici. The analyst expects the acquisition to close on the current terms.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly
See the top stocks recommended by analysts >>
Read More on AMYT:
- Chiesi Farmaceutici S.p.A. to acquire Amryt Pharma
- Chiesi Farmaceutici S.p.A. to Acquire Amryt Pharma Plc
- Amryt Pharma announces results from Phase 3 pediatric trial of lomitapide
- Amryt Announces Positive Top Line Results from Phase 3 Pediatric Trial of Lomitapide in HoFH
- Amryt Pharma receives positive COMP opinion on orphan designation for Mycapssa